Skip to main content
Premium Trial:

Request an Annual Quote

Centogene, Alector Partner to ID Frontotemporal Dementia Patients With Genetic Mutations

NEW YORK – Centogene said on Wednesday that it has partnered with biotechnology firm Alector on an observational study to identify frontotemporal dementia patients with genetic mutations.

Alector, a South San Francisco-based immuno-neurology company developing treatments for neurodegenerative diseases, will provide undisclosed financial support for the effort.

The study, called EFRONT, aims to enroll more than 3,000 FTD patients for genetic testing at centers in Belgium, Germany, Greece, Italy, Portugal, Spain, and Turkey.

"The study will take full advantage of the power of Centogene's unique bio/databank, expertise in neuroscience, and extensive network of neurologists," said Centogene CEO Andrin Oswald in a statement.

“In line with our commitment to improving the lives of patients with frontotemporal dementia, we are pleased to support Centogene's efforts to advance a better and more comprehensive understanding of the genetic underpinnings of FTD through the observational EFRONT study," said Robert Paul, chief medical officer of Alector.

FTD, which currently has no treatments, affects approximately 110,000 patients in the European Union and more than 50,000 in the US. Between 5 and 10 percent of FTD patients harbor a mutation in the progranulin gene, according to Rostock, Germany-based Centogene, and for many others, the disease cause is thought to be genetic.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.